Inovio stock rises 2.5-fold on plasmid DNA drug approval
Inovio Pharma's plasmid DNA-based Voceryq has become the second drug approved in the US for adults with recurrent respiratory papillomatosis.
Aspen, Bambusa close IPOs as Corxel takes SPAC route
Aspen Neuroscience and Bambusa Therapeutics get their Nasdaq IPOs over the line, while Corxel eyes a debut via a blank-cheque company merger.
Sanofi eyeing pipeline deals ahead of Dupixent patent loss
Sanofi's CEO says adding to the group's pipeline through M&A and licensing will be "critical" as it prepares for generic competition to Dupixent.
AZ seeking $1.5bn in annual savings by end-2029
AstraZeneca has launched a cost-cutting programme that will aim to slash $1.5bn a year off its costs, with the savings reinvested in R&D.
Featured Content
Latest News
Views & Analysis
Deep Dive
White Papers & Webinar
Podcasts & Video
Partner Content
11th Liquid Biopsy for Precision Oncology Summit West Coast
Your industry-leading, flagship West Coast meeting uniting the global liquid biopsy community
31st Edition Strategic Project & Portfolio Management for Ph...
The Marcus Evans 31st Edition Strategic Project & Portfolio Management for Pharma conference, for European pharmaceutical PMO and portfolio leaders.
Women in AI - an evening of practical AI learning
Women in AI returns November 10 in London, UK. Join women from across healthcare for an evening of practical AI learning.
UAE investment drives Middle East biopharma transformation a...
Exclusive analysis for World Health Expo (WHX) by Frost & Sullivan forecasts precision medicine growth of more than 10% in the Middle East over the ne
Europe's Largest Gathering for ADC Innovation
Taking place in London from 8-11 March 2027, the 17th World ADC London returns as Europe's largest annual gathering dedicated to the ADC community